Black Diamond Therapeutics will host a webcast on December 3, 2025, to discuss silevertinib trial results and program updates.
Quiver AI Summary
Black Diamond Therapeutics, Inc. will hold a webcast on December 3, 2025, at 8:00am ET to present results from its Phase 2 clinical trial of silevertinib and provide a program update. The webcast can be accessed through the "Events and Presentations" section of their Investors website. Black Diamond is focused on developing MasterKey therapies for genetically defined cancers, particularly targeting oncogenic mutations. Silevertinib is a fourth-generation EGFR inhibitor aimed at treating non-small cell lung cancer and glioblastoma. A replay of the webcast will be available afterward, and investors are encouraged to check the company's website for further information.
Potential Positives
- Announcement of a webcast to present Phase 2 clinical trial results for silevertinib, highlighting progress in oncology development.
- Focus on innovative MasterKey therapies targeting oncogenic mutations, showcasing the company's commitment to addressing genetically defined tumors.
- Continued advancement in clinical trials, particularly in non-small cell lung cancer and glioblastoma, indicating potential for significant therapeutic impact.
Potential Negatives
- The press release does not provide specific results or data from the Phase 2 clinical trial of silevertinib, which could raise concerns about transparency and investor confidence.
- There is no mention of any successful outcomes or milestones from the trial, which may imply potential challenges in the development of their therapies.
- The focus on a single treatment (silevertinib) in the press release may suggest a lack of diversification in their product pipeline, which could be a risk for the company's future prospects.
FAQ
What is the date and time of the Black Diamond webcast?
The Black Diamond webcast is scheduled for Wednesday, December 3, 2025, at 8:00am ET.
How can I access the webcast?
The webcast can be accessed on the Investors section of the Black Diamond website under “Events and Presentations.”
What is the focus of the webcast?
The webcast will present results from the Phase 2 clinical trial of silevertinib and provide a program update.
What type of company is Black Diamond Therapeutics?
Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies targeting oncogenic mutations in cancer patients.
Where can I find additional information about the company?
Additional information can be found on the Black Diamond Therapeutics website or their LinkedIn profile.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BDTX Hedge Fund Activity
We have seen 50 institutional investors add shares of $BDTX stock to their portfolio, and 71 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BELLEVUE GROUP AG removed 2,733,547 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $10,360,143
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 758,709 shares (+549.2%) to their portfolio in Q3 2025, for an estimated $2,875,507
- MARSHALL WACE, LLP added 561,333 shares (+76.1%) to their portfolio in Q3 2025, for an estimated $2,127,452
- ACADIAN ASSET MANAGEMENT LLC added 481,123 shares (+inf%) to their portfolio in Q3 2025, for an estimated $1,823,456
- RENAISSANCE TECHNOLOGIES LLC added 432,300 shares (+258.7%) to their portfolio in Q3 2025, for an estimated $1,638,417
- NORTHERN TRUST CORP added 336,643 shares (+222.3%) to their portfolio in Q3 2025, for an estimated $1,275,876
- J. GOLDMAN & CO LP removed 323,999 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $1,227,956
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$BDTX Analyst Ratings
Wall Street analysts have issued reports on $BDTX in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 11/18/2025
- Stifel issued a "Buy" rating on 10/16/2025
- HC Wainwright & Co. issued a "Buy" rating on 08/11/2025
- Raymond James issued a "Outperform" rating on 07/01/2025
To track analyst ratings and price targets for $BDTX, check out Quiver Quantitative's $BDTX forecast page.
$BDTX Price Targets
Multiple analysts have issued price targets for $BDTX recently. We have seen 5 analysts offer price targets for $BDTX in the last 6 months, with a median target of $9.0.
Here are some recent targets:
- Kelsey Goodwin from Piper Sandler set a target price of $9.0 on 11/18/2025
- Laura Prendergast from Stifel set a target price of $8.0 on 10/16/2025
- Brad Canino from Guggenheim set a target price of $8.0 on 09/04/2025
- Robert Burns from HC Wainwright & Co. set a target price of $10.0 on 08/11/2025
- Sean McCutcheon from Raymond James set a target price of $11.0 on 07/01/2025
Full Release
Webcast to be held Wednesday, December 3, at 8:00am ET
CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, will host a webcast to present results from its Phase 2 clinical trial of silevertinib and provide a program update on Wednesday, December 3, 2025, at 8:00am ET.
Webcast information
The webcast can be accessed under “Events and Presentations” on the Investors section of the Black Diamond website at www.blackdiamondtherapeutics.com . A replay of the webcast will be available following the completion of the event.
About Black Diamond Therapeutics
Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 non-small cell lung cancer (NSCLC) trial of silevertinib, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. For more information, please visit www.blackdiamondtherapeutics.com .
From time to time, we may use our website or our LinkedIn profile at www.linkedin.com/company/black-diamond-therapeutics to distribute material information. Our financial and other material information is routinely posted to and accessible on the Investors section of our website, available at www.blackdiamondtherapeutics.com . Investors are encouraged to review the Investors section of our website because we may post material information on that site that is not otherwise disseminated by us. Information that is contained in and can be accessed through our website or our LinkedIn page is not incorporated into, and does not form a part of, this press release.
Contact
For Investors:
[email protected]
For Media:
[email protected]
